These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20930487)

  • 1. Acceptable incremental cost effectiveness ratio for use of new drugs, cases in statin therapies.
    Nakao S; Kawabe H; Takuma H; Shiragami M
    Yakugaku Zasshi; 2010 Oct; 130(10):1347-52. PubMed ID: 20930487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme.
    Thai LP; Moss JR; Godman B; Vitry AI
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):419-33. PubMed ID: 26707482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacoeconomic analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy for the secondary prevention of coronary heart disease].
    Sato S; Matsushita Y; Kobayashi T; Awata N
    Nihon Eiseigaku Zasshi; 2004 Jul; 59(3):335-41. PubMed ID: 15359898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A French approach to cost-effectiveness analysis?
    de Pouvourville G
    Eur J Health Econ; 2010 Dec; 11(6):521-3. PubMed ID: 21046185
    [No Abstract]   [Full Text] [Related]  

  • 5. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
    Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
    JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
    Maclaine GD; Patel H
    Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program.
    Anderson GM; Kerluke KJ; Pulcins IR; Hertzman C; Barer ML
    Inquiry; 1993; 30(2):199-207. PubMed ID: 8314608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
    Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
    Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals.
    Carlson JJ; Garrison LP; Sullivan SD
    J Manag Care Pharm; 2009 Oct; 15(8):683-7. PubMed ID: 19803557
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins.
    McRae I; van Gool K; Hall J; Yen L
    Appl Health Econ Health Policy; 2017 Oct; 15(5):625-634. PubMed ID: 28660496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden.
    Pettersson B; Hoffmann M; Wändell P; Levin LÅ
    Health Policy; 2012 Jan; 104(1):84-91. PubMed ID: 22115548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying the use of the statin antilipemic drugs: comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia.
    Cooke C; Nissen L; Sketris I; Tett SE
    Clin Ther; 2005 Apr; 27(4):497-508. PubMed ID: 15922822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
    Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
    Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment.
    Schneeweiss S; Patrick AR; Maclure M; Dormuth CR; Glynn RJ
    Circulation; 2007 Apr; 115(16):2128-35. PubMed ID: 17420348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.